Pulse nav.journalClub Aktive Debatten Trends Entdecken Fragen Forschende

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Start Entdecken nav.journalClub Trends

⌘+K

Potential 20-week Faricimab Dosing in Wet Age-Related Macular Degeneration | Synapse

February 11, 2026Open Access

Potential 20-week Faricimab Dosing in Wet Age-Related Macular Degeneration

Key Points

To evaluate the effects of a 20-week dosing schedule of faricimab in patients with wet age-related macular degeneration.
Evaluated patients with nAMD in TENAYA/LUCERNE trials
Analyzed outcomes over a 2-year period
Assessed the potential for extended dosing intervals based on protocol allowances.
Patients on extended dosing maintained robust disease control for 2 years.
56% of patients could potentially benefit from every-20-week dosing if permitted.

Abstract

Patients with nAMD in TENAYA/LUCERNE always on extended faricimab dosing (≥12-weeks) achieved robust disease control throughout 2 years. Additionally, 56% of patients could have potentially extended to every-20-week dosing had the protocol allowed.

Read Full Paperexternally

Like

Bookmark

Share

View Full Paper

Cite This Study

Ambresin et al. (Sun,) studied this question.

synapsesocial.com/papers/698c1bb8267fb587c655d8ce https://doi.org/https://doi.org/10.1016/j.oret.2026.02.001

Like

Bookmark

Share

View Full Paper